Show simple item record

dc.contributor.authorGuney, Sabri
dc.contributor.authorDemireli, FUAT HULUSİ
dc.contributor.authorErdamar, Sibel
dc.contributor.authorBuyukunal, Evin
dc.contributor.authorElcin, Olgun
dc.contributor.authorTural, Deniz
dc.contributor.authorYildiz, Ozcan
dc.contributor.authorSerdengecti, Suheyla
dc.date.accessioned2021-03-03T12:50:32Z
dc.date.available2021-03-03T12:50:32Z
dc.date.issued2014
dc.identifier.citationTural D., Yildiz O., Elcin O., Erdamar S., Guney S., Demireli F. H. , Buyukunal E., Serdengecti S., "What is the optimal treatment in clinical stage T3N0M0 rectal cancer?", JOURNAL OF BUON, cilt.19, sa.1, ss.97-102, 2014
dc.identifier.issn1107-0625
dc.identifier.othervv_1032021
dc.identifier.otherav_306d6967-864c-4569-85f2-a3546e1e36b1
dc.identifier.urihttp://hdl.handle.net/20.500.12627/37047
dc.description.abstractPurpose: Some previous studies suggested that certain rectal cancer patients with stage T3N0 and favorable features may be adequately treated with surgery and adjuvant chemotherapy. However, the optimal management of clinical (c) T3N0 rectal adenocarcinoma based on preoperative imaging is unclear. In this study, we aimed to determine the frequency of lymph node metastases in patients clinically staged as T3N0 rectal adenocarcinoma following preoperative chemoradiotherapy (CTR).
dc.language.isoeng
dc.subjectOnkoloji
dc.subjectSağlık Bilimleri
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleWhat is the optimal treatment in clinical stage T3N0M0 rectal cancer?
dc.typeMakale
dc.relation.journalJOURNAL OF BUON
dc.contributor.departmentAkdeniz Üniversitesi , ,
dc.identifier.volume19
dc.identifier.issue1
dc.identifier.startpage97
dc.identifier.endpage102
dc.contributor.firstauthorID14592


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record